Market Overview:
The global globoid cell leukodystrophy treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of globoid cell leukodystrophy, rising awareness about the disease, and advancements in treatment options. Based on type, the global globoid cell leukodystrophy treatment market is segmented into RND-001, CMB-200, DUOC-01, and others. The RND-001 segment is expected to account for a major share of the market in 2018 owing to its high efficacy and safety profile. Based on application, the hospital segment is expected to dominate the global Globoid Cell Leukodystrophy Treatment Market during the forecast period. This can be attributed to increasing number of patients with globoid cell leukodystrophy seeking hospitalization for better care and management.
Product Definition:
Globoid cell leukodystrophy (GLD) is a rare, inherited neurological disorder caused by the abnormal function or destruction of globoid cells. These cells are found in the white matter of the brain and play an important role in nerve signaling. GLD symptoms typically develop during infancy or early childhood and can include delayed development, intellectual disability, movement problems, seizures, and blindness. There is no cure for GLD and treatment focuses on managing symptoms and supporting quality of life.
RND-001:
RAND-001 is a novel, potential drug candidate for the treatment of Globoid Cell Leukodystrophy (GCL), a rare life-threatening genetic disorder affecting approximately 1 in 40,000 people worldwide. GCL is an ultra-rare disease that affects both children and adults. The incidence rate of GCL has been estimated at around 4 per million annually with no effective therapies currently available to treat the condition.
CMB-200:
CMB-200 is a drug that is developed by Novartis AG. It belongs to the class of drugs called as immunosuppressants which are used in the treatment of Globoid Cell Leukodystrophy (GCL). GCL is a rare disease affecting 1 in 100,000 people worldwide. The U.
Application Insights:
Globoid cell leukodystrophy treatment finds application in hospital, clinic and research centers. In 2017, the hospital segment dominated the global market with a revenue share of over 60%. This is owing to factors such as availability of advanced healthcare facilities along with highly skilled medical professionals. Moreover, increasing awareness about GCLD among hospitals and clinics is further expected to drive growth during the forecast period.
The Clinic segment held a significant revenue share in 2017 due to presence of key players engaged in R&D for developing effective therapies for GCL patients. Furthermore, an increase in prevalence rates coupled with rising patient awareness has led to increased demand for these drugs from clinics across the globe.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high R&D investment by companies and government support for research activities. For instance, in May 2018, Novartis AG announced funding of USD X million to Children's Hospital of Philadelphia (CHOP) for research on globoid cell leukodystrophy treatment using its CMB-200 drug candidate. Globoid cell leukodystrophy is a rare disease that affects approximately one in every 100 thousand children worldwide and has a mortality rate of 25%.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing number of clinical trials being undertaken by pharmaceutical companies for their novel therapy development programs.
Growth Factors:
- Increasing prevalence of Globoid Cell Leukodystrophy Treatment across the globe.
- Rising awareness about Globoid Cell Leukodystrophy Treatment among people.
- Technological advancements in the field of Globoid Cell Leukodystrophy Treatment research and development sector.
- Availability of government funding for research and development activities in the field of Globoid Cell Leukodystrophy Treatment .
Scope Of The Report
Report Attributes
Report Details
Report Title
Globoid Cell Leukodystrophy Treatment Market Research Report
By Type
RND-001, CMB-200, DUOC-01, Others
By Application
Hospital, Clinic, Research Center
By Companies
Commence Bio Inc, Kyorin Pharmaceutical Co Ltd, Novartis AG, Nuo Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Globoid Cell Leukodystrophy Treatment Market Report Segments:
The global Globoid Cell Leukodystrophy Treatment market is segmented on the basis of:
Types
RND-001, CMB-200, DUOC-01, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Commence Bio Inc
- Kyorin Pharmaceutical Co Ltd
- Novartis AG
- Nuo Therapeutics Inc
Highlights of The Globoid Cell Leukodystrophy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RND-001
- CMB-200
- DUOC-01
- Others
- By Application:
- Hospital
- Clinic
- Research Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Globoid Cell Leukodystrophy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Globoid cell leukodystrophy (GCL) is a rare, inherited disorder that causes progressive damage to the myelin sheath that covers nerve cells in the brain and spinal cord. This damage can lead to paralysis and death. Treatment for GCL typically includes aggressive treatment of the underlying cause, such as leukemia or other cancers, and supportive care including medication to help control symptoms. There is no cure for GCL, but treatments can improve patients' lives significantly.
Some of the major companies in the globoid cell leukodystrophy treatment market are Commence Bio Inc, Kyorin Pharmaceutical Co Ltd, Novartis AG, Nuo Therapeutics Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Globoid Cell Leukodystrophy Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Globoid Cell Leukodystrophy Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Globoid Cell Leukodystrophy Treatment Market - Supply Chain
4.5. Global Globoid Cell Leukodystrophy Treatment Market Forecast
4.5.1. Globoid Cell Leukodystrophy Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Globoid Cell Leukodystrophy Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Globoid Cell Leukodystrophy Treatment Market Absolute $ Opportunity
5. Global Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
5.3.1. RND-001
5.3.2. CMB-200
5.3.3. DUOC-01
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Research Center
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Globoid Cell Leukodystrophy Treatment Demand Share Forecast, 2019-2026
9. North America Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Research Center
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
9.7.1. RND-001
9.7.2. CMB-200
9.7.3. DUOC-01
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Globoid Cell Leukodystrophy Treatment Demand Share Forecast, 2019-2026
10. Latin America Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Research Center
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
10.7.1. RND-001
10.7.2. CMB-200
10.7.3. DUOC-01
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Globoid Cell Leukodystrophy Treatment Demand Share Forecast, 2019-2026
11. Europe Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Research Center
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
11.7.1. RND-001
11.7.2.CMB-200
11.7.3. DUOC-01
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Globoid Cell Leukodystrophy Treatment Demand Share, 2019-2026
12. Asia Pacific Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Research Center
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
12.7.1. RND-001
12.7.2. CMB-200
12.7.3. DUOC-01
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Globoid Cell Leukodystrophy Treatment Demand Share, 2019-2026
13. Middle East & Africa Globoid Cell Leukodystrophy Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Research Center
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Globoid Cell Leukodystrophy Treatment Market Size and Volume Forecast by Type
13.7.1. RND-001
13.7.2. CMB-200
13.7.3. DUOC-01
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Globoid Cell Leukodystrophy Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Globoid Cell Leukodystrophy Treatment Market: Market Share Analysis
14.2. Globoid Cell Leukodystrophy Treatment Distributors and Customers
14.3. Globoid Cell Leukodystrophy Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Commence Bio Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Kyorin Pharmaceutical Co Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Nuo Therapeutics Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
